NeuroDex research library
Regulatory and trial design: putting a blood biomarker into a CNS study
A biomarker is only useful if it holds up for the decision it supports. These articles cover lab standards (CLIA, GLP, GCLP), companion diagnostics, endpoints, longitudinal variability, multi-site studies, feasibility on banked samples and what to ask of a biomarker service provider.
Lab standards and providers
CLIA vs. GLP vs. GCLP: What Each Means for a Biomarker LaboratoryExplore the essential differences in laboratory standards and quality practices in our guide to CLIA vs GLP vs GCLP.What to Demand From a CNS Biomarker Service ProviderChoosing a CNS biomarker service provider? Four criteria matter most: regulatory validation, reproducibility, tissue provenance and trial readiness.Your End-to-End Partner for the Isolation and Profiling of Neuron-Derived Extracellular Vesicles (NDEs)Explore how NeuroDex isolates and profiles Neuron-Derived Extracellular Vesicles for neurological disorder research.
Companion diagnostics
Companion Diagnostic Development on a Blood-Based CNS BiomarkerCNS biomarker companion diagnostic development fails on provenance, not sensitivity. What FDA and EU regulators require, and how to sequence the work.Companion Diagnostic Development for Blood-Based CNS BiomarkersBlood-based CNS biomarkers can support a companion diagnostic only if they prove brain origin. What clinical validation requires, and where NDEVs fit.
Designing the biomarker plan
Interpreting Blood-Based CNS Biomarkers: 4 Questions for Trial TeamsBlood-Based CNS Biomarkers: 4 Questions for Any ResultHow Blood-Based CNS Biomarkers Improve Trial EndpointsBlood-Based CNS Biomarkers demonstrably improve CNS trial enrollment.How Do You Add a Brain-Specific Biomarker to a Trial Panel?Your plasma panel sums signal across tissues. How to add a brain-specific biomarker, tissue-of-origin readout to an existing CNS trial panel without a…More Draws, Better Decisions: Blood Biomarker Variability in Longitudinal Trial DesignBlood biomarker variability in neurodegenerative disease decides whether longitudinal sampling helps a trial. Build schedules that track brain, not…Before You Add a Blood Biomarker to Your Trial, Test It on Samples You Already HaveTest a blood biomarker on samples you already have before it enters your protocol. How to source, screen, design, and read a banked-sample pilot…Turnaround, Batching, and Data Deliverables in a Multi-Site CNS Biomarker StudyPlanning a multi-site CNS biomarker study? Site drift, plate effects and thin data files erode blood biomarker signal. How to design pre-analytics and…Carrying a Biomarker Signal From Animal Model to First-in-HumanPreclinical CNS biomarker signals often fail in human blood. Here’s how to design a bridging study that carries a brain signal from model to…

